PMID: 589554Dec 1, 1977

Combination therapy for multiple myeloma

Cancer
R AlexanianJ Weick

Abstract

The effect of six different chemotherapy regimens were evaluated in 462 previously untreated patients with multiple myeloma. In comparison with other treatments, drug combinations that included vincristine and were given at 3-week intervals were associated with higher response rates and longer survival times. No gain was noted from the use of Adriamycin or from combinations of alkylating agents unless vincristine was given and the treatment intervals were short. Seventy-one responding patients were allocated at random to maintenance treatment with intermittent courses of either azathioprine--prednisone or a combination of melphalan--cyclophosphamide--carmustine (BCNU)--prednisone. The survival time was not prolonged with either maintenance treatment in comparison with that for responding patients continued on other therapies or on no therapy in previous studies. Attempts to reduce tumor was maximally with a change in the therapeutic modality, such as with immunotherapy or radiotherapy, remain to be evaluated.

Citations

Jan 1, 1982·Cancer Chemotherapy and Pharmacology·G MerliniS Perugini
Jan 1, 1988·European Journal of Clinical Pharmacology·U LoosH J Dengler
Jan 1, 1991·Life Sciences·P PasqualettiG Natali
Oct 1, 1983·European Journal of Cancer & Clinical Oncology·A PaccagnellaM V Fiorentino
Mar 1, 1984·Cancer Treatment Reviews·K Rieche
Jan 1, 1996·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·P PasqualettiR Casale
Dec 1, 1982·Cancer Treatment Reviews·R B Weiss, B F Issell
Jul 26, 1979·The New England Journal of Medicine·O R McIntyre
Oct 4, 1979·The New England Journal of Medicine·D E BergsagelA B Miller
Feb 14, 1980·The New England Journal of Medicine·D C Case
Feb 10, 1983·The New England Journal of Medicine·R A Kyle
May 2, 2002·Anti-cancer Drugs·S Zweegman, P C Huijgens
Jun 1, 1979·Australian and New Zealand Journal of Medicine·B M Colls, B A Darlow
Jun 24, 1978·British Medical Journal
Aug 19, 1978·British Medical Journal·J S Malpas, D Parker
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
Jul 1, 1987·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R MisianiG Mecca
Sep 1, 1990·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A KorzetsJ Walls
Jan 1, 1979·Medical and Pediatric Oncology·F J CummingsP Calabresi
Feb 1, 1990·American Journal of Hematology·R AlexanianS Tucker
Nov 13, 2007·Hematology/oncology Clinics of North America·Angela Dispenzieri
Feb 1, 1984·European Journal of Cancer & Clinical Oncology·H KantarjianR Alexanian
Jul 12, 1980·Lancet·B G DurieS Salmon
Apr 1, 1983·European Journal of Cancer & Clinical Oncology·A AhreB Wadman
Jun 1, 1983·European Journal of Cancer & Clinical Oncology·O A van DobbenburghH O Nieweg
Jan 1, 1985·Leukemia Research·M TribaltoR Centurioni
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P PasqualettiD Colantonio
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BladéM Fontanillas
Oct 1, 1986·European Journal of Cancer & Clinical Oncology·J BladéB Nomdedeu
Jun 1, 1988·European Journal of Cancer & Clinical Oncology·D PeestI Schedel
Feb 1, 1981·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B HouwenH O Nieweg
Dec 1, 1981·British Journal of Haematology·M M Oken, N E Kay
Oct 1, 1984·Australian and New Zealand Journal of Medicine·N W BoyceR C Atkins
Dec 1, 1982·British Journal of Haematology·A Valentin-OpranM E Arlot
Sep 29, 1984·Clinica Chimica Acta; International Journal of Clinical Chemistry·J J StĕpánE Silinková-Málková
Feb 1, 1997·Hematology/oncology Clinics of North America·M Boccadoro, A Pileri
Jul 1, 1991·Cancer·J C LaskerM Lane
Jan 15, 1986·Cancer·H van der LelieA E von dem Borne
Apr 15, 1981·Cancer·R AlexanianA Haut
Feb 1, 1984·Cancer·R Alexanian, R Dreicer
Aug 28, 2020·Frontiers in Oncology·Luis Gerardo Rodríguez-LobatoSophia Danhof
Nov 1, 1987·European Journal of Haematology·D A Galton, F Brito-Babapulle
Jan 1, 1989·European Journal of Haematology. Supplementum·M BaccaraniC Gallizia
Dec 1, 1982·American Journal of Hematology·R Dreicer, R Alexanian
Feb 23, 2021·Oncology and Therapy·Dhauna Karam, Shaji Kumar

Related Concepts

Antineoplastic Agents
Azathioprine Sulfate
BiCNU
Cyclophosphamide, (S)-Isomer
Ribodoxo
Polychemotherapy
Medphalan
Multiple Myeloma
Rectodelt
Remission, Spontaneous

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.